SurGenTec® Achieves Key Milestone with Expanded Indications for OsteoFlo® HydroFiber™
This expansion of indications now includes use as a bone void filler for the treatment of tumors, cysts, trauma, and osteomyelitis. This landmark clearance represents a significant advancement in the capabilities of SurGenTec®’s cutting-edge technology and highlights the company’s commitment to enhancing patient care in orthopedic and spine surgery.
July 22, 2025